

# **Evaluation of hydro-alcoholic extract of *Clerodendrum myricoides* (Hochst. Vatke) leaves and its solvent fractions in pentylenetetrazole-induced convulsion in Mice**

## **ABSTRACT**

**Introduction:** Epilepsy is a chronic neurological disorder that affects people of all ages. Herbal medicines are widely used across the globe due to their wide applicability and therapeutic efficacy. The low side effects of traditional herbal medicines have encouraged many types of research into antiepileptic activity. *Clerodendrum myricoides* is a plant whose leaves extract is traditionally used as an anticonvulsant in Ethiopia.

**Objective:** The aim of this study was to evaluate the anticonvulsant effect of the hydro-alcoholic extract and solvent fractions of *C. myricoides* leaves against pentylenetetrazole-induced seizures in mice.

**Methods:** Comparison of mean latency to onset of convulsion, mean duration of convulsions and proportion of percentage protection against seizure of the plant extract was tested against PTZ-induced seizures. Three different doses were used by giving them orally 30 minutes before subcutaneous pentylenetetrazole (80 mg/kg) administration with the positive (diazepam 2 mg/kg) and negative (physiological saline 10 mg/kg) control groups. Data were presented as mean  $\pm$  standard error of the mean and analyzed using one-way analysis of variance (ANOVA) and followed by posthoc Tukey's multiple comparisons test.  $P < 0.05$  was considered statistically significant.

**Results:** The crude extract of *C. myricoides*, with the doses of 300, 600, 1,200 mg/kg showed a significant delay in mean latency to onset of seizures [299.33 $\pm$ 30.129 sec ( $p < 0.05$ ); 387.167 $\pm$  27.6 sec ( $p < 0.01$ ); 417.833 $\pm$ 31.9 sec ( $p < 0.001$ ); respectively]; decrease in the duration of convulsion [27.333 $\pm$ 1.585 sec ( $p < 0.05$ ); 16.833 $\pm$ 1.537 sec ( $p < 0.01$ ); 10.50 $\pm$ 0.671 sec ( $p < 0.001$ ) respectively]; and a proportion of percentage protection of mice against seizure [16.33% (1/6); 33.33% (2/6); 50% (3/6) respectively] in a dose-dependent manner compared to the control group [92.833 $\pm$ 13.006 sec; 34.167 $\pm$ 3.683 sec, 0% respectively]. *C. myricoides* anticonvulsant activity was less than that of diazepam [1001.16 $\pm$  68.430 sec, 4.500 $\pm$ 0.619, 83.33 sec, 83.33% respectively for the doses]. Its solvent fractions, however, didn't show a significant anticonvulsant effect.

**Conclusion:** The hydroalcoholic leaves crude extract of *C. myricoides* has anticonvulsant activity but its solvent fractions do not have comparable significant effects.

**Keywords:** - Anticonvulsant effects, hydro-alcoholic extracts, solvent fractions, *Clerodendrum myricoides*, pentylenetetrazole.

## **1. INTRODUCTION**

Epilepsy is a neurological condition that affects a large segment of the world population. It is a disease of the brain characterized by the erratic and intermittent incidence of a transient change of behavior due to chaotic, simultaneous, and recurrent firing of cortical neurons known as a seizure [1].

A seizure is a paroxysmal abnormal discharge at high frequency from an aggregate of neurons in the cerebral cortex; while epilepsy is a condition described by repetitive events of such seizures. Seizures can be "non-epileptic" when evoked in a normal brain by treatment such as electric shock or chemical convulsants or "epileptic" when occurring without evident provocation [1, 2]. Epilepsy affects about 1% of the world population. The frequency of epilepsy in industrialized nations is roughly 50 in 100,000, while that of undeveloped nations is 100 in 100,000. It has been observed that currently available antiepileptic drugs are unable to control seizures effectively [3, 4].

Contemporary drug treatment of epilepsy is complicated by the incapability of medications to control seizures in certain patients and by adverse effects ranging from minimal damage of the brain to death resulting from aplastic anemia

or hepatic failure. Thus, the efficacy and safety of the current medication remain a challenge [5-8]. As a result, about 30% of epileptic patients continue to suffer recurrent seizures even with current antiepileptic drug therapy [9].

Cultural attitudes, lack of prioritization of epilepsy as a public health condition, poor wellbeing framework foundation, and lack of supplies of antiepileptic drugs to upset suitable treatment [10, 11]. The point of treating an epileptic patient is not only to eliminate the event of seizures but also to help them lead a self-sustained life [9]. Hence, there is a need to look for more effective and safer alternative antiepileptic agents.

Herbal medicine continues to serve a large proportion of the population, especially those in rural and tribal areas, regardless of the advent of modern medicine. Evaluation of the safety and efficacy of traditional medicinal plants through experimental models provides further clues that may prove any claim on the use of plants as medicine [12].

*Clerodendrum myricoides* (Hochst.) Vatke (Family: Lamiaceae) commonly called Blue-flowered tinder wood, locally known as Marasissa, in Afaan Oromoo and Misirich, in Amharic, is traditionally claimed to have antiepileptic activity in Ethiopia, and it is also a common medicinal plant in Africa [13, 14].

## 2. MATERIALS AND METHODS

### 2.1. Collection and preparation of Plant Materials

Fresh leaves of *Clodendrum myricoides* (Family: Lamiaceae) were collected, from Bale National Park, Ethiopia, 550km away from Addis Ababa and transported in a dark plastic bag to avoid decomposition by light. The plant material was then authenticated and given a voucher number (AAU-NH 01T) by a plant Taxonomist and the plant specimen was deposited at the National Herbarium, College of Computational and Natural Sciences, Addis Ababa University for future reference.

The fresh leaves were dried under shade at room temperature and powdered using pestle and mortar. The dried powder (800g) was macerated in 70% v/v of ethanol for three days continuously stirred using an orbital shaker at 120 rpm and then, filtered using gauze (0.1mm<sup>2</sup>mesh) and Whatman filter paper (size 15cm) (Whatman® England). The filtrate was then placed in a Petri dish, and kept deep-frozen at -27<sup>0</sup>C and lyophilized for one week (-52<sup>0</sup>C, 133 x 10-3mbar, operan, Korean vacuum limited, Korea) to obtain crude extract. A total yield of 83.52g crude extract was obtained and kept in a desiccator until used for the experiment.

The crude extract of *C. myricoides* was further fractionated using petroleum ether, dichloromethane, ethanol, and water as solvents in order of decreasing polarity. Twenty grams of hydroethanolic extract of *C. myricoides* was dissolved in 100 ml of distilled water in a separate funnel. The dissolved ethanol extract was partitioned with 3x150 ml of petroleum ether at 40-60 °C. The petroleum ether partitions were combined and concentrated using a rota-vapor (BÜCHI Rota-vapor R-205, Switzerland). The concentrate was labeled as petroleum ether fraction and yielded 2.03 g. The aqueous residue was then partitioned with 3x150 ml of dichloromethane. The dichloromethane filtrates were combined and evaporated to give 2.88 g of dichloromethane fraction. The aqueous residue was further partitioned with 3x100 ml ethanol. The fractionates were then combined, concentrated, and labeled as 3.98 g yield of ethanol fraction. The remaining aqueous residue was lyophilized to dryness using lyophilizer (operan, Korean vacuum limited, Korea) and labeled as 8.65 g yield of aqueous residue. All the fractions were then kept in different separate tightly closed containers with aluminum foil in a desiccator until used for the experiment.

### 2.2. Drugs/chemicals/test substances preparation and administration

Pentylentetrazol (PTZ) (Sigma Chemical Co., Sweden), diazepam (Medifarma Pharmaceuticals) and sodium chloride (BDH, England) were used in this study. All chemicals were prepared freshly just before use. Dimethyl sulfoxide (DMSO), ethanol, dichloromethane, petroleum ether (Germany). PTZ and diazepam were dissolved in saline solution (0.9% w/v). The crude extract and its fractions were dissolved in distilled water and DMSO (2:1v/v) mixture. Drug solutions were prepared according to the supplier's instructions. The maximum volume of freshly prepared herbal medicine administered at once in rodents was 1 ml/100 g body weight according to OECD guidelines (Buschmann, 2013). The starting dose of *C. myricoides*, crude extract to be administered was 300 mg/kg of body weight, 1/10<sup>th</sup> of LD<sub>50</sub>.

### 2.3. Experimental procedure

Male *BALB/c* mice weighing between 22-30 g were obtained from Ethiopian Public Health Institute, Addis Ababa, Ethiopia and housed at room temperature under standard nutritional and environmental conditions with relative moisture

of 30-70% and 12 hours light-dark cycle. They all had access to water and food *ad libitum* and were denied food 12h before experimentation. The animals were arbitrarily assigned to 9 treatment groups consisting of 6 mice each.

Group I received the vehicle (normal saline, 10 ml/kg, i.p) and served as a negative control; Group II received diazepam (2 mg/kg, p.o.), the standard drug and served as a positive control; Groups III, IV, and V received three different doses (300, 600 and 1,200 mg/kg) of the crude extract and Groups VI-IX received 1,200 mg/kg of the four solvent fractions each (petroleum ether, dichloromethane, ethanol and aqueous), 30 min before subcutaneous injection of PTZ (80 mg/kg) into the loose skin fold on the back of the neck of the animals. After PTZ administration, mice were placed in a chamber and closely observed for 30 minutes for the onset time of convulsions, and the duration of convulsion. Delayed onset and decreased duration of convulsion indicate the ability of the extract to protect animals from PTZ-induced convulsion.

## 2.4. Statistical analysis

The Numbers of animals without convulsions were calculated as percentages. All results were expressed as mean  $\pm$  SEM. Statistical significance between the groups was analyzed by one-way analysis of variance (Sigma Plot 14 (Sigma Plot Software, Inc., La Jolla, CA, USA) software) followed by Tukey's post hoc multiple comparison tests for comparison between groups. For all the tests,  $P < 0.05$  was considered statistically significant.

## 3. RESULTS

### 3.1 Yields of hydro-ethanolic extract and its solvent fractions of *C. myricoides*.

The yields of the crude extract and solvent fractions of *C. myricoides* leaves extract are shown in Tables 1.

Table 1. *C. myricoides* 70% ethanol extract and its solvent fraction yield.

Plant Material	Yields obtained in gram	% of yield
<i>C. myricoides</i> (crude extract)	83.52	10.44
Petroleum ether fraction	2.03	10.15
Dichloromethane fraction	2.88	14.4
Ethanol fraction	3.98	19.9
Aqueous residue	8.65	43.25

### 3.2. Effects of hydro-alcoholic crude extract of *C. myricoides* on onset of seizure

The crude extract of *C. myricoides* at the doses of 300, 600, and 1200 mg/kg body weight showed significant delay or increase in latency [299.33 $\pm$ 30.129 sec ( $p < 0.05$ ); 387.167 $\pm$ 27.6 sec ( $p < 0.01$ ); 417.833 $\pm$ 31.9 sec ( $p < 0.001$ ), respectively] to mean onset of seizures in a dose-dependent manner against PTZ-induced seizures compared to the control group [92.833 $\pm$ 13.006 sec]. The measured anticonvulsant activity was less than that of diazepam [1001.16 $\pm$  68.430sec] as shown in Fig.1.




Fig.1. Comparison of the mean latency to the onset of convulsion in groups mice to hydroalcoholic *C. myricoides* crude extract (300mg/kg, 600mg/kg, and 1200mg/kg) 30 min before subcutaneous PTZ administration with the positive (diazepam 2mg/kg) and negative (physiological saline 10mg/kg) control groups. Values are mean  $\pm$  SEM of three independent experiments ( $n=6$ ). SEM=Standard error of the mean, Cm= *C. myricoides* hydro-alcoholic crude extract. DZP=diazepam, Ctrl=Control.  $P=0.05^*$ ,  $p<0.01^{**}$ ,  $p<0.001^{***}$ .

### 3.3. Effects of hydro-alcoholic crude extract of *C. myricoides* on duration of convulsion

The crude extract of *C. myricoides* at the doses of 300, 600, and 1200mg/kg body weight significantly decreased the severity or the duration [27.333  $\pm$ 1.585 sec ( $p<0.05$ ); 16.833 $\pm$ 1.537 sec ( $p<0.01$ ); 10.50 $\pm$ 0.671 sec ( $p<0.001$ ), respectively] of convulsions in a dose-dependent manner against PTZ- induced seizures compared to the control group [34.167 $\pm$ 3.683 sec]. The observed anticonvulsant activity was similar to that of diazepam [4.500 $\pm$ 0.619 sec] as depicted in Fig.2.




Fig.2. Comparison of the mean duration of convulsion in groups of mice to the hydro-alcoholic crude extracts of *C. myricoides* (300, 600, and 1200 mg/kg) 30 min before subcutaneous PTZ administration with the positive (diazepam 2mg/kg) and negative (physiological saline 10mg/kg) control groups. Values represent mean  $\pm$  SEM of three independent experiments ( $n=6$ ). SEM=Standard error of the mean, Cm= *C. myricoides* hydro-alcoholic crude extract. DZP=diazepam, Ctrl=Control.  $*P < 0.05$ ,  $**p<0.01$ ,  $***p<0.001$ .

### 3.4. Protective effect of crude extract of *C. myricoides* against PTZ-induced seizures

All the doses (300, 600 and 1200 mg/kg body weight) of the crude extract of *C. myricoides* showed a proportion of percentage protection of the animals against seizure [16.33% (1/6); 33.33% (2/6); 50% (3/6), respectively] against PTZ-induced seizure in a dose-dependent manner compared to the negative control [0%], The observed proportion of percentage protection was less than that of diazepam [83.33%,(5/6)] as indicated in Fig. 3.




Fig.3. The percentage protection of hydro-ethanolic *C. myricoides* crude extract (300, 600, and 1,200) mg/kg of body weight 30 min before subcutaneous PTZ administration compared with those of the positive (diazepam 2mg/kg) and negative (physiological saline 10mg/kg) controls. Cm= *C. myricoides*, DZP=diazepam, Ctrl=Control. N=6.

### 3.5. Effects of solvent fractionation of *C. myricoides* on onset of seizure

The solvent fractions of *C. myricoides* did not show statistically a significant difference ( $p>0.05$ ) in latency to onset of seizures against PTZ-induced seizures compared to the control group, as shown in fig.4.




Fig.4. Comparison of the mean latency to the onset of convulsion in groups that received 1,200mg/kg each solvent fractions (water, ethanol, dichloromethane, and Petroleum fractions) of hydro-alcoholic *C. myricoides* crude extract 30 min before subcutaneous PTZ administration with the positive (diazepam 2mg/kg) and negative (physiological saline 10mg/kg) control groups. Values are mean  $\pm$  SEM of three independent experiments ( $n=3$ ). SEM=Standard error of mean, CmFw= *C. myricoides* water fraction, CmFe= *C. myricoides* ethanol fraction, CmFd= *C. myricoides* dichloromethane fraction, CmFp= *C. myricoides* petroleum ether fraction, DZP=diazepam, Ctrl=Control.

### 3.6. Effects of solvent fractionation of *C. myricoides* on duration of convulsion

The solvent fractions of *C. myricoides* did not show a statistically significant difference in the severity of seizures or duration of convulsions against PTZ-induced seizures compared to the control group but the difference was significant to that of diazepam as indicated in fig.5.




Fig.5. Comparison of the mean duration of convulsion in those mice group which received solvent fractions of hydroalcoholic *C. myricoides* crude extract 1,200mg/kg each (water, ethanol, dichloromethane, and petroleum ether fractions) 30 min before subcutaneous PTZ administration with the positive (diazepam 2mg/kg) and negative (physiological saline 10mg/kg) control groups. Values represent mean  $\pm$  SEM of three independent experiments ( $n=3$ ). SEM=Standard error of the mean, CmFw= *C. myricoides* water fraction, CmFe= *C. myricoides* ethanol fraction, CmFd= *C. myricoides* dichloromethane fraction, CmFp= *C. myricoides* petroleum ether fraction, DZP=diazepam, Ctrl=Control.

#### 4. DISCUSSION

In the present study, the anticonvulsant effect of hydroalcoholic and solvent fractions of *Clerodendrum myricoides* extract was investigated in the PTZ-induced convulsion model in mice. In this experiment, when the hydroalcoholic extract *C. myricoides* leaves were tested against PTZ-induced seizure in mice, the onset of convulsion was prolonged and the duration of convulsion was shortened significantly. This anticonvulsant effect of the extract is likely mediated through central nervous system neurotransmitter-dependent depressant effect. This central nervous system depressant effect was assessed by prior induction of convulsion using a centrally acting pentylenetetrazole.

It is well known that pentylenetetrazole (PTZ) induction seizure is mediated through inhibition of GABAergic neurotransmission, which is through inhibition of the activity of gamma-aminobutyric acid (GABA) at GABA<sub>A</sub> receptors [16, 17].

Enhancement of GABA neurotransmission attenuates convulsions; while inhibition of neurotransmission of GABA heightens convulsions [18, 19]. GABA is an endogenous agonist of the GABA<sub>A</sub> receptor boosting opening of the channels to Cl<sup>-</sup> ions in the neuronal plasma membrane inducing hyperpolarization bringing. This effect blocks nerve impulse transmission and henceforth responsible for the counter epileptic actions [20]. It has been found that PTZ also increases the neurotoxic free radicals in the brain leading to neuronal damage-induced epilepsy [21, 22]. The PTZ test in an experimental animal can be taken as a model for human generalized and absence seizures [23, 24]. Diazepam is a known standard antiepileptic drug that generally inhibits sodium currents and enhances GABA transmission in the brain, consequently blocking PTZ-induced seizure [19].

The observation that the crude hydroalcoholic extract of *clerodendrum myricoides* significantly increased latency to onset of seizures, decreased the severity of seizures, and showed a proportion of percentage protection against PTZ-induced seizure in a dose-dependent manner clearly shows the anticonvulsant activity of the extract. This observed anticonvulsant effect of the extract might well be attributed to the direct and/or indirect enhancement action on GABAergic neurotransmission in the brain [16, 17].

Our findings are in agreement with those of the study done on the anticonvulsant effect of *Antiaris toxicaria* (Pers.) and pycnogenol extract from maritime pine bark (*Pinus pinaster*) containing flavonoids [25, 26] and on the root extract of *Carissa carandas* Linn and fruit extract *Phoenix dactylifera* [19, 27].

Neither of the fractions, i.e., petroleum ether, dichloromethane, ethanol, and an aqueous fraction, however, showed a significant protective effect against PTZ-induced seizures. This negative effect of the solvent extract is probably related to the presence of low concentrations of the active ingredients in each of such solvent fractions. Therefore, our observation shows that the anticonvulsant effect of crude extract as compared to its separate solvent extract might be

related to an additive and/or synergistic effect of the active ingredients present in the crude extract. These findings are in agreement with other similar studies in which solvent fractions were reported to be ineffective against PTZ-induced seizures [14, 28, 29].

## 5. CONCLUSION

From the present findings, it can be concluded that hydro-alcoholic crude extract of *Clerodendrum myricoides* has an anticonvulsant effect against PTZ-induced seizures. The effect is likely attributed to the presence of different active ingredients in the extract that exert a synergistic effect. The solvent fractions of *C. myricoides* do not have the same anticonvulsant activity. These finding also justifies the traditional claim of the use of the plant in the treatment of epilepsy.

## ETHICAL APPROVAL

The protocol was approved by the Institutional Review Board, College of health sciences, Addis Ababa University (Protocol number; 053/15/Physio). Before, during, and after the study animals were handled according to OECD guidelines [15].

## COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

## REFERENCES

1. James OM. Drugs effective in the therapy of epilepsy. The pharmacological basis of therapeutics. 2001; 10:521-47.
2. Wannang NN, Anuka JA, Kwanashie HO, Gyang S, Auta A. Anti-seizure activity of the aqueous leaf extract of *Solanum nigrum* linn (solanaceae) in experimental animals. African Health Sciences. 2008;8(2).
3. Santhosh NS, Sinha S, Satishchandra P. Epilepsy: Indian perspective. Annals of Indian Academy of Neurology. 2014 Mar; 17(Suppl 1):S3.
4. Holmes GL, Noebels JL. The epilepsy spectrum: targeting future research challenges. Cold Spring Harbor perspectives in medicine. 2016 Jul 1;6(7):a028043.
5. Holmes GL. Critical issues in the treatment of epilepsy. American Journal of Hospital Pharmacy. 1993 Dec 1;50 (12\_Suppl):S5-16.
6. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia. 1995 Feb; 36:S46-65.
7. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia. 1995 Feb; 36:S13-26.
8. Roger JP, Brian SM. Antiepileptic drugs in katzung, B, G. ed. Basic and clinical pharamacology. 7th edition Stanford: Appleton & lange. 1998:386-408.
9. Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals. 2010 Jul;3(7):2090-110.
10. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we go from here?. Bulletin of the World Health Organization. 2001; 79:344-51.
11. Amoateng P, Woode E, Kombian SB. Anticonvulsant and related neuropharmacological effects of the whole plant extract of *Synedrella nodiflora* (L.) Gaertn (Asteraceae). Journal of pharmacy & bioallied sciences. 2012 Apr;4(2):140.
12. Kosalge SB, Fursule RA. Investigation of ethnomedicinal claims of some plants used by tribals of Satpuda Hills in India. Journal of Ethnopharmacology. 2009 Jan 30;121(3):456-61.
13. Yineger H, Kelbessa E, Bekele T, Lulekal E. Plants used in traditional management of human ailments at Bale Mountains National Park, Southeastern Ethiopia. Journal of Medicinal Plants Research. 2013 Sep 28;2(6):132-53.
14. Maina EN, Njau VN, Gavamukulya Y. Phytochemical Analysis and Antileishmanial Activity of *Clerodendrum myricoides* and *Salvadora persica* Plant Extracts against *Leishmania major*. Journal of Complementary and Alternative Medical Research. 2020 Feb 26:29-44.
15. Buschmann J. The OECD guidelines for the testing of chemicals and pesticides. In Teratogenicity Testing 2013 (pp. 37-56). Humana Press, Totowa, NJ.

16. De Sarro A, Cecchetti V, Fravolini V, Naccari F, Tabarrini O, De Sarro G. Effects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced seizures in mice. *Antimicrobial agents and chemotherapy*. 1999 Jul 1;43(7):1729-36.
17. Ojewole JA. Analgesic and anticonvulsant properties of *Tetrapleura tetraptera* (Taub)(Fabaceae) fruit aqueous extract in mice. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2005 Dec; 19(12):1023-9.
18. Tamboli AM, Rub RA, Ghosh P, Bodhankar SL. Antiepileptic activity of lobeline isolated from the leaf of *Lobelia nicotianaefolia* and its effect on brain GABA level in mice. *Asian Pacific journal of tropical biomedicine*. 2012 Jul 1; 2(7):537-42.
19. Hegde K, Thakker SP, Joshi AB, Shastry CS, Chandrashekhar KS. Anticonvulsant activity of *Carissa carandas* Linn. root extract in experimental mice. *Tropical Journal of Pharmaceutical Research*. 2009;8(2).
20. Son HL, Yen PT. Preliminary phytochemical screening, acute oral toxicity and anticonvulsant activity of the berries of *Solanum nigrum* Linn. *Tropical Journal of Pharmaceutical Research*. 2014 Sep 15; 13(6):907-12.
21. Peng QL, Buz'Zard AR, Lau BH. Pycnogenol® protects neurons from amyloid- $\beta$  peptide-induced apoptosis. *Molecular Brain Research*. 2002 Jul 15;104(1):55-65.
22. Choi J, Yoo Y, Park H. Inhibitory effects of the Korean red ginseng extract on the content of neurotransmitter-related components of the mouse brain in convulsion-induced model. *Natural Product Sciences*. 2007;13(4):384.
23. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. *Epilepsy research*. 1988 May 1; 2(3):145-81.
24. Upton N. Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. *Trends in pharmacological sciences*. 1994 Dec 1;15(12):456-63.
25. Mante PK, Adongo DW, Woode E, Kukuia KK, Ameyaw EO. Anticonvulsant effect of *Antiaris toxicaria* (Pers.) Lesch.(Moraceae) aqueous extract in rodents. *International Scholarly Research Notices*. 2013; 2013.
26. Goel R, Saxena P. Pycnogenol protects against pentylenetetrazole-induced oxidative stress and seizures in mice. *Current clinical pharmacology*. 2019 Apr 1;14(1):68-75.
27. Sameh Mohamed Mostafa., EL-Nabtity., Ahmed Shaban Abdelaziz., Manar Salah Moselhi., Mario Giorgi., 2019. Anticonvulsant Activity of Hydro-alcoholic *Phoenix dactylifera* Fruit Extract and *Pimpinella anisum* Oil in Mice. *American Journal of Animal and Veterinary Sciences*, 14 (2): 127.138.
28. Rao VS, Rao A, Karanth KS. Anticonvulsant and neurotoxicity profile of *Nardostachys jatamansi* in rats. *Journal of ethnopharmacology*. 2005 Dec 1;102(3):351-6.
29. Kouamé, N. M., Koffi, C., N'Zoué, K. S., Yao, N. A. R., Doukouré, B., Kamagaté, M. *Comparative Antidiabetic Activity of Aqueous, Ethanol, and Methanol Leaf Extracts of Persea americana and Their Effectiveness in Type 2 Diabetic Rats. Evidence-Based Complementary and Alternative Medicine, 2019, 1–14. doi:10.1155/2019/5984570*